Scissortail Wealth Management LLC Makes New $1.01 Million Investment in Amgen Inc. (NASDAQ:AMGN)

Scissortail Wealth Management LLC acquired a new position in Amgen Inc. (NASDAQ:AMGN) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 3,220 shares of the medical research company’s stock, valued at approximately $1,009,000.

Several other institutional investors have also added to or reduced their stakes in the stock. Moneta Group Investment Advisors LLC grew its position in shares of Amgen by 83,875.6% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 7,541,011 shares of the medical research company’s stock worth $1,980,571,000 after buying an additional 7,532,031 shares during the period. Norges Bank purchased a new stake in shares of Amgen in the 4th quarter worth about $1,351,778,000. Price T Rowe Associates Inc. MD grew its position in shares of Amgen by 158.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,950,013 shares of the medical research company’s stock worth $774,791,000 after buying an additional 1,806,456 shares during the period. International Assets Investment Management LLC purchased a new stake in shares of Amgen in the 4th quarter worth about $4,589,900,000. Finally, Morgan Stanley grew its position in shares of Amgen by 12.9% in the 4th quarter. Morgan Stanley now owns 13,301,365 shares of the medical research company’s stock worth $3,493,471,000 after buying an additional 1,523,665 shares during the period. 76.50% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts recently commented on the stock. Raymond James assumed coverage on shares of Amgen in a research report on Thursday, March 28th. They set a “market perform” rating on the stock. StockNews.com downgraded shares of Amgen from a “buy” rating to a “hold” rating in a research report on Thursday, March 28th. Oppenheimer reaffirmed an “outperform” rating and set a $350.00 price target on shares of Amgen in a report on Thursday, February 1st. BMO Capital Markets raised shares of Amgen from a “market perform” rating to an “outperform” rating and raised their price target for the company from $286.00 to $326.00 in a report on Tuesday, December 19th. Finally, Leerink Partnrs downgraded shares of Amgen from an “outperform” rating to a “market perform” rating in a report on Wednesday, February 7th. Ten equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $295.30.

Amgen Trading Up 0.0 %

NASDAQ AMGN traded up $0.13 on Tuesday, hitting $265.64. 2,017,570 shares of the stock were exchanged, compared to its average volume of 2,871,780. The company has a debt-to-equity ratio of 10.14, a quick ratio of 1.13 and a current ratio of 1.65. The stock has a fifty day moving average price of $279.63 and a two-hundred day moving average price of $281.52. The firm has a market capitalization of $142.36 billion, a P/E ratio of 21.26, a P/E/G ratio of 2.53 and a beta of 0.58. Amgen Inc. has a 52-week low of $211.71 and a 52-week high of $329.72.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, February 6th. The medical research company reported $4.71 earnings per share for the quarter, topping the consensus estimate of $4.66 by $0.05. The business had revenue of $8.20 billion during the quarter, compared to the consensus estimate of $8.13 billion. Amgen had a return on equity of 154.27% and a net margin of 23.83%. The business’s revenue for the quarter was up 19.8% compared to the same quarter last year. During the same period last year, the company earned $4.09 earnings per share. Research analysts forecast that Amgen Inc. will post 19.49 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be issued a $2.25 dividend. The ex-dividend date is Thursday, May 16th. This represents a $9.00 dividend on an annualized basis and a yield of 3.39%. Amgen’s dividend payout ratio is presently 72.06%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.